L. Robson

发表

Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1.

L. Aarons, M. Ranson, T. Ward, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma

G. Jayson, P. Vasey, F. Blackhall, 2003, British Journal of Cancer.

A Phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid

A. Boddy, S. Wedge, D. Newell, 2004, Investigational New Drugs.

Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer.

Stephen J. Morris, L. Aarons, M. Ranson, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of pharmacologically based dosing of carboplatin with filgrastim support in women with epithelial ovarian cancer.

M. Millward, F. Chapman, A. Calvert, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions.

A. Boddy, F. Chapman, A. Calvert, 1995, Seminars in oncology.

Pharmacological study of CT-2103 (XyotaxTM), a poly(L-glutamic acid)-paclitaxel conjugate administered every 3 weeks or every 2 weeks in a phase I study

J. Sludden, A. Boddy, D. Bisset, 2001 .

Antitumor activity without on-target off-tumor toxicity of GD2–chimeric antigen receptor T cells in patients with neuroblastoma

K. McHugh, I. Dragoni, A. Akarca, 2020, Science Translational Medicine.

A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer.

A. Boddy, A. Calvert, H. Thomas, 1997, British Journal of Cancer.

Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors

A. Harris, A. Boddy, N. Curtin, 2008, Clinical Cancer Research.

A Phase I and Pharmacokinetic Study of Paclitaxel Poliglumex (XYOTAX), Investigating Both 3-Weekly and 2-Weekly Schedules

J. Sludden, A. Boddy, D. Bissett, 2005, Clinical Cancer Research.

Final clinical, pharmacokinetic and pharmacodynamic results of the phase I study of the novel poly(ADP-ribose)polymerase (PARP) inhibitor, AG014699, in combination with temozolomide

A. Harris, A. Boddy, N. Curtin, 2005 .

Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT)

D. Bissett, C. Twelves, J. Cassidy, 2004, British Journal of Cancer.

A phase I trial of AEG35156 (XIAP antisense) administered as a continuous intravenous infusion in patients with advanced tumors.

M. Ranson, T. Ward, C. Dive, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors

R. Plummer, A. Calvert, M. Middleton, 2005 .

Phase 1 pharmacokinetic (PK) study of CT-2103 given Q2 or Q3 weeks in patients with solid tumors

J. Sludden, A. Boddy, D. Bissett, 2003 .

Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors

A. Harris, A. Boddy, N. Curtin, 2008, Clinical Cancer Research.

Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study.

A. Boddy, D. Newell, A. Calvert, 1996, Seminars in oncology.